首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1140690

全球抗癌藥物市場-2022-2029

Global Oncology Therapy Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

在預測期內（2022-2029 年），癌症治療的市場規模預計將以 7.3% 的複合年增長率增長。

抗癌藥物是旨在通過阻斷某些有助於惡性細胞生長和擴散的分子（如蛋白質和 DNA）來減緩癌症生長和擴散的藥物。肺癌、結腸癌、乳腺癌、腎癌和其他器官的癌症在人群中很普遍。癌症治療很大程度上取決於疾病的進展程度。它通常包括放射療法、化學療法、手術和其他癌症治療。目前正在研究免疫療法、靶向療法、激素療法和乾細胞移植，並正在進行臨床試驗。

市場動態

主要驅動力是由於癌症發病率上升導致對抗癌藥物的需求增加，對精準醫療的需求增加，製藥公司之間的合作夥伴關係增加，最近的技術進步，癌症研究活動的增加，全球是老年人口的增加。此外，全球醫療保健支出的增加。

最近的技術進步和信息利用率的提高預計將推動市場增長。

先進的醫療設備、大數據、人工智能和移動應用程序推動了更好的患者參與。大數據通過提供患者導航、患者報告的結果、高風險患者的識別、患者滿意度評分和適當的治療來促進護理。AI 使用 DL 算法和卷積神經網絡 (CNN) 來分析來自腫瘤圖像的像素級信息。例如，許多國家越來越多地使用移動應用程序是技術進步的結果，這些進步可以增強癌症診斷、治療、依從性和患者體驗的其他方面。基因泰克還批准了一種名為嵌合抗原受體 T 細胞（CAR-T）療法的新藥，以改善 CAR-T 療法。雖然這種療法對患者來說相當昂貴，但首個 CAR-T 療法的推出也見證了一項創新的基於績效的合同的揭幕，以使其更容易獲得。

此外，新型放射性標記藥物的持續存在降低了癌症患者的風險和死亡率。該藥物將放射性同位素 LU 附著在奧曲□上，奧曲□與腫瘤細胞結合，使輻射成為可能，並直接靶向癌細胞。因此，預計最近的技術進步將推動市場發展。

抑製劑

然而，與使用抗癌藥物相關的副作用的發生以及與抗癌藥物開發相關的高成本是預計阻礙腫瘤藥物市場增長的幾個主要因素。

行業分析

腫瘤藥物市場根據各種行業因素（如未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行深入分析。

細分分析

靶向治療部分預計將佔癌症治療市場的最大市場份額。

靶向治療領域在 2021 年佔據了最大的市場份額。該細分市場受益於與傳統療法相比副作用更少、更具成本效益以及增加運動次數的療法。此外，靶向療法包括激素療法、細胞凋亡誘導劑、基因表達調節劑、血管生成抑製劑、PARP抑製劑、信號抑製劑和毒素遞送分子。這些藥物減緩癌細胞的生長和擴散，並限制對正常細胞的傷害。此外，該地區的 FDA 批准也在增加。例如，Trodelvy（sacituzumab govitecan-hziy）於2020年4月獲得美國食品藥品監督管理局批准，用於治療成年三陰性乳腺癌患者。Trodelvy 是針對 Trop-2 受體的 Trop-2 定向抗體和有助於癌症生長、分裂和傳播的拓撲異構□抑製劑的組合。此外，tabrecta（卡馬替尼）於 2020 年 5 月獲得美國 FDA 批准用於治療成人非小細胞肺癌（NSCLC）患者，使其成為 FDA 批准的首個用於治療具有特定突變的 NSCLC 的靶點。一種藥物。因此，從上述描述來看，市場細分在預測期內佔據了最大的市場份額。

區域分析

預計北美將在全球抗癌藥物市場佔有最大的市場份額。

2021 年，北美的收入份額最高。癌症患病率的增加、癌症治療的創新、治療臨床試驗的增加、該地區 FDA 批准的增加以及市場參與者的產品發布將在預測期內推動市場。這是一個因素。例如，美國癌症協會估計，到 2020 年，美國將有 180 萬例新的癌症病例和 606,520 例癌症死亡。與此同時，到 2021 年，估計美國將診斷出 190 萬例新的癌症病例，將有 608,570 例癌症死亡。因此，癌症治療藥物的採用正在取得進展。此外，2021 年 5 月，安進的 LUMAKRAS（sotrasib）獲得 FDA 批准，用於治療具有 KRAS G12C 突變的局部晚期或轉移性非小細胞肺癌（NSCLC）成人患者。因此，從上述描述來看，北美地區在預測期內佔據了最大的市場份額。

競爭格局

腫瘤藥物市場的主要關鍵參與者是Pfizer, Inc.、Novartis、Amgen Inc、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Company、Johnson and Johnson等。

Merck &Co Inc.

概述

是一家專業從事處方藥、生物治療藥物、疫苗和獸藥的研究、開發、生產和營銷的生物製藥公司。我們提供心血管、癌症、免疫疾病、傳染病、呼吸系統和婦女疾病的處方藥，以及糖尿病藥物。它銷售動物保健產品，如疫苗、家禽、牛和水產養殖產品。Merck &Co Inc.為藥品批發商、零售商、醫院、政府機構和託管醫療機構提供藥品，並向獸醫、分銷商和畜牧業者提供獸藥。該公司的子公司和附屬公司在美洲、歐洲、中東和非洲、亞太地區和拉丁美洲開展業務。

產品介紹

KEYTRUDA（派姆單抗）。KEYTRUDA 是一種處方藥，用於治療一種稱為黑色素瘤的皮膚癌。用於患有 IIB 期、IIC 期和 III 期黑色素瘤的成人和 12 歲以上兒童，以幫助預防手術切除黑色素瘤和含有癌症的淋巴結後復發。

該報告提供了大約 45 多個市場數據表、40 多個圖表和 180 頁有關全球腫瘤學市場的信息。

Market Overview

Oncology Therapy Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.3% during the forecast period (2022-2029).

Cancer therapies are medications designed to limit cancer growth and proliferation by interfering with specific molecules involved in the growth and expansion of malignant cells, such as proteins or DNA. Cancers of the lung, colorectal, breast, kidney and other organs are common in the population. The stage of disease progression primarily determines cancer treatment. It typically comprises radiotherapy, chemotherapy, surgery, and other cancer therapies. Immunotherapy, targeted therapy, hormone therapy, and stem cell transplant are now being researched and tested in clinical studies.

Market Dynamics

The major driving forces are the rise in cancer incidences, which has led to increased demand for cancer drugs, increased demand for precision medicine, increased number of collaborations between the pharmaceutical companies, increased recent advances in technology, and increased research activities in cancer, increasing geriatric population globally. In addition, the rise in healthcare expenditure worldwide and the rise.

An increase in the number of recent advances in technology and the use of information is expected to drive market growth.

Advanced medical devices, big data, artificial intelligence, and mobile apps drive better patient engagement. Big data has made treatments easier as it provides patient navigation, patient-reported outcomes, identification of high-risk patients, patient satisfaction scoring, and appropriate treatment. AI uses DL algorithms and convolutional neural networks (CNN), which analyze pixel-level information from images in oncology. For instance, the increasing usage of mobile apps in many nations results from technological advancements that can enhance cancer diagnosis, treatment, adherence, and other elements of the patient experience. In addition, Genentech approved a new medicine called Chimeric Antigen Receptor T-cell (CAR-T) therapy to improve CAR-T therapy. The therapy is quite expensive for patients, but an innovative pay-for-performance contract was also revealed in conjunction with the launch of the first CAR-T therapy to make it more accessible.

Furthermore, the new radio-labeled drug sustainability has lowered cancer patients' risk and death rate. The medicine is composed of radioisotope LU attached to octreotide that binds the tumor cells, enables the radiation, and directly targets the cancer cells. Thus, the recent advancements in technology are expected to boost the market.

Restraint:

However, the onset of adverse effects associated with the use of cancer drugs and high costs related to cancer drug development is among a few major factors expected to hamper the growth of the oncology therapy market.

Industry Analysis

The oncology therapy market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Targeted therapy segment is expected to hold the largest market share in the oncology therapy market.

The targeted therapy segment accounted for the largest market share in 2021. The segment benefited due to its fewer side effects offered by the treatment than the conventional therapy and cost-effective nature, and its increased number of dynamics. Moreover, the targeted therapy includes hormone therapies, apoptosis inducers, gene expression modulators, angiogenesis inhibitors, PARP inhibitors, signal transduction inhibitors, and toxin delivery molecules. These drugs inhibit the growth and spread of cancer cells and limit harm to normal cells. In addition, there are increasing FDA approvals in the region. For instance, Trodelvy (sacituzumab govitecan-hziy) was approved by the US Food and Drug Administration in April 2020 for treating adult patients with triple-negative breast cancer. Trodelvy is a drug combination of a Trop-2-directed antibody and a topoisomerase inhibitor that targets the Trop-2 receptor, which aids cancer growth, division, and dissemination. Furthermore, Tabrecta (capmatinib) was authorized by the US FDA in May 2020 to treat adult patients with non-small cell lung cancer (NSCLC), making it the first FDA-approved targeted medication to treat NSCLC with particular mutations. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global oncology therapy market.

North America accounted for the highest revenue share in 2021. The increasing prevalence of cancer, innovations in the cancer therapies, rising clinical trials for the therapies, increasing FDA approvals in the region and product launches by the market players are the factors to drive the market in the forecast period. For instance, For instance, according to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of oncology therapies. Moreover, the FDA approved Amgen's LUMAKRAS (sotorasib) in May 2021 to treat adult patients with KRAS G12C-mutated locally progressed or metastatic non-small cell lung cancer (NSCLC). Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the oncology therapy market are Pfizer, Inc., Novartis, Amgen Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson Others.

Merck & Co Inc.:

Overview:

Merck & Co Inc (Merck) is a biopharmaceutical firm specializing in researching, developing, producing, and marketing prescription medications, biologic therapies, vaccines, and animal health products. It provides prescription medications for cardiovascular, cancer, immunological disorders, infectious, respiratory, and women's diseases, as well as diabetic therapy. The company sells animal health items such as vaccinations, poultry, cattle, and aquaculture products. Merck offers pharmaceuticals to drug wholesalers, retailers, hospitals, government agencies, managed health care providers, and animal health products to veterinarians, distributors, and livestock producers. The company's subsidiaries and affiliates operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

Product Portfolio:

KEYTRUDA (pembrolizumab): KEYTRUDA is a prescription medicine used to treat: a kind of skin cancer called melanoma. It may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

The global oncology therapy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

1. Scope and Methodology

1.1. Research Methodology
1.2. Scope of the market

2. Key Trends and Developments

2.1. Key Trends and Developments

3. Executive Summary

3.1. Market Snippet By Treatment
3.2. Market Snippet By types DataM CLO Scenario

4. Market Dynamics

4.1. Market impacting factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising incidence
  - 4.1.1.2. Driver 2
- 4.1.2. Restraints
  - 4.1.2.1. Onset of adverse effects
  - 4.1.2.2. Restraint 2

5. Industry Analysis

5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Patent analysis

6. By Treatment

6.1. Introduction
6.2. Market size analysis, and y-o-y growth analysis (%), By Treatment segment
6.3. Market attractiveness index, By Treatment segment
6.4. Targeted therapy
- 6.4.1. Introduction
- 6.4.2. Market size analysis, y-o-y growth analysis (%)
6.5. Immunotherapy
- 6.5.1. Introduction
6.6. Chemotherapy
6.7. Radiation therapy
6.8. Others

7. By Type

7.1. Introduction
7.2. Market size analysis, and y-o-y growth analysis (%), By Type segment
7.3. Market attractiveness index, By Type segment
7.4. Breast cancer
- 7.4.1. Introduction
- 7.4.2. Market size analysis, y-o-y growth analysis (%)
7.5. Lung cancer
- 7.5.1. Introduction
7.6. Blood cancer
7.7. Kidney cancer
7.8. Hematological cancer
7.9. Prostate cancer
7.10. Gastrointestinal cancer
7.11. Gynecologic cancer
7.12. Others

8. By End-users

8.1. Introduction
8.2. Market size analysis, and y-o-y growth analysis (%), By End-users segment
8.3. Market attractiveness index, By End-users segment
8.4. Hospitals
- 8.4.1. Introduction
- 8.4.2. Market size analysis, y-o-y growth analysis (%)
8.5. Specialty clinics
- 8.5.1. Introduction
8.6. Cancer and radiation therapy centers

9. By Region

9.1. Introduction
9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key region-specific dynamics
- 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
- 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
- 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
- 9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
  - 9.4.6.1. U.S.
  - 9.4.6.2. Canada
  - 9.4.6.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
- 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
- 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
- 9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
  - 9.5.6.1. Germany
  - 9.5.6.2. U.K.
  - 9.5.6.3. France
  - 9.5.6.4. Italy
  - 9.5.6.5. Spain
  - 9.5.6.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
- 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
- 9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
- 9.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
  - 9.6.6.1. Brazil
  - 9.6.6.2. Argentina
  - 9.6.6.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
- 9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
- 9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
- 9.7.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
  - 9.7.6.1. China
  - 9.7.6.2. India
  - 9.7.6.3. Japan
  - 9.7.6.4. Australia
  - 9.7.6.5. Rest of Asia Pacific
9.8. The Middle East And Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment

10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type

11. Competitive Landscape

11.1. Competitive scenario
11.2. Competitor strategy analysis
11.3. Comparative type portfolio analysis
11.4. Market positioning/share analysis
11.5. Mergers and acquisitions analysis

12. Company Profiles

12.1. Pfizer, Inc.
- 12.1.1. Company Overview
- 12.1.2. Type Portfolio And Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Novartis
12.3. Amgen Inc
12.4. AstraZeneca PLC
12.5. Bayer AG
12.6. Bristol-Myers Squibb Company
12.7. Johnson and Johnson
12.8. Others